|
J. Kevin Buchi was elected to serve as a member of the board of directors in June 2004. He has served as Senior Vice President, Finance and Chief Financial Officer of Cephalon, Inc. since April 1996, and previously held several financial positions with Cephalon, including Controller, since joining the company in March 1991. Cephalon, a Nasdaq-traded company, discovers, develops and markets innovative products to treat neurological and sleep disorders, cancer and pain. At Cephalon, Mr. Buchi has been involved in raising significant working capital through secondary debt offerings, convertible preferred stock and debt, bank debt, private placements/structural financing and derivative strategies. He is also involved with the acquisitions of product and companies, as well as developing and executing growth strategies. He previously worked at E.I. duPont de Nemours and Company, at PricewaterhouseCoopers as a senior auditor and at Eastman Kodak Co. as a production chemist. Mr. Buchi is also a director of Lorus Therapeutics, a for-profit biotechnology company. He is a graduate of Cornell University with a BA in Chemistry and a minor in Economics, and holds an MBA from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. | 